Enforcement, Litigation, and Compliance Conference: For the Drug, Device, Food, and Tobacco Industries

Overview

Get ready for the 2026 Enforcement, Litigation, and Compliance Conference—your key meeting for staying ahead in an increasingly complex federal and state regulatory environment. This premier annual event brings together leaders from industry, government, and private practice to explore the latest trends and emerging issues shaping FDA enforcement and compliance across drug, device, food, and tobacco industries.

Hear directly from top officials at FDA, DOJ, and other agencies, and gain practical insights into recent developments in civil and criminal litigation, as well as notable cases and settlements. Connect with key stakeholders and leave better equipped to navigate risk and maintain compliance in a rapidly evolving landscape.

Register

Registration will open soon

FDLI invites you to submit a topic proposal for a session at the Enforcement, Litigation, and Compliance Conference. Your submissions and input are integral to ensuring that the most timely and pertinent topics are covered at the conference. Topics should address timely and important issues relating to enforcement, compliance, or litigation issues as it affects the FDA-regulated community. Topics can be related to a specific FDA-regulated product (e.g., drugs, biologics, medical devices, tobacco and nicotine products, cosmetics, cannabis products, or food and dietary supplements) or be relevant to all. Thank you in advance for your submission!

The Call for Proposals will be open through May 11, 2026.

Proposal Submission Guidelines 

• Proposed topics should be at an advanced level.
• Provide important details and context: why the topic is important, who is affected, and relevant regulatory, legislation, guidance, or newsworthy developments.
• As a neutral convener, FDLI prefers topics that include multiple perspectives, including government, industry, private attorneys, academics, and public interest.
• FDLI prefers submissions to include a reasonably detailed and thoughtful title for and description of the proposed session.

Submissions FAQ 

• Q: Am I limited in the number of proposals I can submit?
  • A: Multiple submissions from the same person or organization are welcome; however, each proposal requires its own form.
• Q: How will my submission be reviewed?
  • A: All submissions are blinded before being reviewed by the Conference Planning Committee. All submissions are treated as recommendations, and proposals may be modified or combined by FDLI to best suit the needs of the conference.
• Q: Do all items in my proposal need to be in final form?
  • A: No—Your proposal does not need to be in final form. A proposal can and will likely be updated by the Committee to include the newest or most up-to-date information as relevant for the FDLI audience.
• Q: Should I reach out to speakers I suggest in advance of submitting my proposal?
  • A: Suggested speakers should not be invited in advance—sessions are often combined, and we cannot guarantee that suggested speakers will be included.
• Q: Can I email you my submission?
  • A: All submissions must be received through the submission portal.
• Q: If my topic is selected, do I get to speak? Do I have to speak if my topic is selected?
  • A: Speaking opportunities are generally reserved for FDLI members. If your topic is selected, you will be invited to speak if you are interested; however, speaking is not a requirement to submit a topic.
• Q: How will I know if my submission is accepted?
  • A: You will be notified of the status of your submission approximately three months before the conference date.

Proposal Submission Timeline 

• May 11, 2026: Call for Proposals closes.
• August 2026: Those who submitted proposals will be notified of their submission’s status.

Sponsors

Sponsorship opportunities are available. Contact Cathy Scolieri for more information. View 2026 Sponsorship Opportunities

Planning Committee

Committee Members

Hannah R. Bornstein, Nixon Peabody LLP
Trevor Bridges, Juul Labs
Brian Burgess, Goodwin Procter LLP
Yetunde Fadahunsi, GE Healthcare
Pamela Forrest, Covington & Burling LLP
Ryan Gooley, Sedgwick
Teresa Gorecki, Compliance Architects LLC
Perham Gorji, Alston & Bird LLP
Monica C. Groat, Latham & Watkins LLP
Dennis C. Gucciardo, Morgan, Lewis & Bockius LLP
Samuel Hampsher-Monk, Applied Research and Analysis Company LLC
Sean Hilscher, Strategic Compliance Services, Inc. 
Samantha Hong, Kleinfeld, Kaplan & Becker, LLP
Danielle C. Humphrey, Becton Dickinson (BD)
Anne Kanyusik Yoakum, FUJIFILM Holdings America Corporation
Brandon Moss, Wiley LLP
Clint Narver, McGuireWoods LLP
Sonia W. Nath, Cooley LLP
Tina Papagiannopoulos, Manatt, Phelps & Phillips, LLP
Arun Rao, Mayer Brown LLP
James R. Ravitz, McDermott Will & Schulte LLP
Lisa Re, Arnold & Porter LLP
Agustin E. Rodriguez, Troutman Pepper Locke
Gabriel H. Scannapieco, Arnall Golden Gregory LLP
Collin Stabler, Exponent, Inc.
Jessica Tierney, Jones Day
Marc Wagner, BakerHostetler
Anne K. Walsh, Hyman, Phelps & McNamara, PC
Beth P. Weinman, Ropes & Gray LLP
Jack Wenik, Epstein Becker & Green, PC
Benjamin K. Wolf, Alston & Bird LLP
Ashley Zborowsky, Medtronic